Paclitaxel Protein-bound Particles For Injectable Suspension (albumin-bound) Injection, Powder, Lyophilized, For Suspension
NDC Package 24979-710-51

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Paclitaxel Protein-bound Particles For Injectable Suspension (albumin-bound) (paclitaxel) injection is paclitaxel is used to treat various types of cancer. This formulation utilizes a injection, powder, lyophilized, for suspension delivery system. Marketed by Upsher-smith Laboratories, Llc, this product is identified by NDC 24979-710 and is authorized under FDA application NDA021660.

Identification & Billing

NDC Package Code
24979-710-51
Package Description
1 VIAL, SINGLE-USE in 1 CARTON / 20 mL in 1 VIAL, SINGLE-USE
Product Code
24979-710
11-Digit Billing Format
24979071051
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Paclitaxel Protein-bound Particles For Injectable Suspension (albumin-bound)
Non-Proprietary Name
Paclitaxel
Substance Name
Paclitaxel
Dosage Form
Injection, Powder, Lyophilized, For Suspension - A liquid preparation, intended for parenteral use that contains solids suspended in a suitable fluid medium and conforms in all respects to the requirements for Sterile Suspensions; the medicinal agents intended for the suspension are prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
PACLITAXEL 100 mg/20mL
Pharmacologic Class
Usage Information
Paclitaxel is used to treat various types of cancer. It is a cancer chemotherapy drug that works by slowing or stopping cancer cell growth.

Regulatory & Marketing

Labeler Name
Upsher-smith Laboratories, Llc
Product Type
Human Prescription Drug
FDA Application #
NDA021660
Marketing Category
NDA AUTHORIZED GENERIC - A product marketed as a "generic" drug under an approved New Drug Application (NDA), rather than an Abbreviated New Drug Application (ANDA),.
Start Marketing Date
04-01-2022
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J9264
Source: ASP
Paclitaxel protein bound
HCPCS Dosage 1 MG
Units / Pkg 100

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 24979-710-51 identifies a specific commercial package of 1 vial, single-use in 1 carton / 20 ml in 1 vial, single-use of Paclitaxel Protein-bound Particles For Injectable Suspension (albumin-bound), a human prescription drug labeled by Upsher-smith Laboratories, Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This injection, powder, lyophilized, for suspension is formulated for intravenous use and contains paclitaxel as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Upsher-smith Laboratories, Llc on April 01, 2022. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Paclitaxel is used to treat various types of cancer. It is a cancer chemotherapy drug that works by slowing or stopping cancer cell growth.

How is this Upsher-smith Laboratories, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 24979071051. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
24979-710-51
11-Digit CMS (5-4-2)
24979-0710-51

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.